Sign in
Taking people in United StatesEarly phase 1

Vumerity for blood vessel function and walking in peripheral artery disease

Tests Vumerity against placebo for vessel function and walking in peripheral artery disease.

Key facts

Who runs it
University of Nebraska
Where
Omaha, United StatesSee the site
Trial code
Registry title
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease
Status
Recruiting
Phase
Early phase 1
People taking part
20 people, planned
Started
14 Nov 2024
Expected to end
Dec 2026
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Vumerity
  • Placebo
Record updated
24 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with peripheral artery disease (narrowed leg arteries) who get leg pain when walking. It is also looking for people of similar age without this disease as a comparison group.

Age
50-75 years
Sex
Men and women. Women must be past menopause (no periods for more than 24 months).
Disease stage
People with the disease: Fontaine stage II-III, with a history of leg pain during exercise (claudication). Comparison group: no sign of artery blockage (ankle-brachial index > 0.90).
Earlier treatment
People cannot join if they are currently taking dimethyl fumarate.
Biomarker or test result
Normal kidney function (estimated glomerular filtration rate >= 60 mL/min), normal liver tests and blood counts within set ranges, or stable values within the last 6 months.

Main reasons for not taking part

  • Pain at rest, ulcers, gangrene or tissue loss in the foot (Fontaine stage IV)
  • Walking limited by conditions other than the artery disease
  • Pregnant or breastfeeding
  • Multiple sclerosis, psoriasis, or gut disorders such as moderate IBS or Crohn's disease
  • Allergy to diroximel fumarate, dimethyl fumarate or any ingredient of VUMERITY

The registry criteria, word for word

Show all 37 criteriaShow less

Who can take part

  • Peripheral artery disease (PAD) participants:
  • Able to provide written informed consent
  • 50-75 years of age
  • Diagnosed as Fontaine stage II-III
  • History of exercise-induced claudication
  • Females must be postmenopausal (cessation of menses for > 24 months)
  • Normal renal function (serum creatinine-estimated glomerular filtration rate >= 60 mL/min) or evidence of stable renal function within the last 6 months
  • Normal hepatic function (alanine transaminase < 87.5 U/L, alkaline phosphatase < 260 U/L, total bilirubin 1.8 mg/dL) or evidence of stable hepatic function within the last 6 months
  • Complete blood count:; Females: red blood cell 4-5 trillion cells/L, hemoglobin 12-15 g/dL, hematocrit 34-45%, white blood cell count 3-10 billion cells/L, platelet count 160-380 billion/L, and normal lymphocyte count > 700 million lymphocytes/L, or evidence of stable blood counts within the last 6 months; Males: red blood cell 4-6 trillion cells/L, hemoglobin 13-17 g/dL, hematocrit 38-49%, white blood cell count 3-10 billion cells/L, platelet count 135-320 billion/L, and normal lymphocyte count > 700 million lymphocytes/L, or evidence of stable blood counts within the last 6 months; Age-matched control participants:
  • Able to provide written informed consent
  • 50-75 years of age
  • No evidence of peripheral occlusive disease (ankle-brachial index > 0.90)
  • Females must be postmenopausal (cessation of menses for > 24 months)
  • Normal renal function (serum creatinine-estimated glomerular filtration rate >= 60 mL/min), or evidence of stable renal function within the last 6 months
  • Normal hepatic function (alanine transaminase < 87.5 U/L, alkaline phosphatase < 260 U/L, total bilirubin 1.8 mg/dL ), or evidence of stable hepatic function within the last 6 months
  • Complete blood count:; Females: red blood cell 4-5 trillion cells/L, hemoglobin 12-15 g/dL, hematocrit 34-45%, white blood cell count 3-10 billion cells/L, platelet count 160-380 billion/L, and normal lymphocyte count > 700 million lymphocytes/L; Males: red blood cell 4-6 trillion cells/L, hemoglobin 13-17 g/dL, hematocrit 38-49%, white blood cell count 3-10 billion cells/L, platelet count 135-320 billion/L, and normal lymphocyte count > 700 million lymphocytes/L, or evidence of stable blood counts within the last 6 months

Who cannot take part

  • Concomitant use of dimethyl fumarate
  • Peripheral artery disease (PAD) participants:
  • Acute lower extremity ischemic event secondary to thromboembolic disease or acute trauma
  • Limited walking capacity from conditions other than PAD
  • Diagnosis of gastrointestinal disorders (e.g., moderate IBS, Crohn's disease, etc
  • Hypersensitivity to diroximel fumarate, dimethyl fumarate, or to any of the excipients of VUMERITY
  • Blood work and medical history NOT demonstrating:; Normal renal function (serum creatinine-estimated glomerular filtration rate >> 60 mL/min); Normal hepatic function (alanine transaminase 0-35 IU/L, alkaline phosphatase 30-120 IU/L, total bilirubin 2-17 micromoles/L),
  • Complete blood count NOT within ranges:; Females: red blood cell 4-5 trillion cells/L, hemoglobin 12-15 g/dL, hematocrit 34-45%, white blood cell count 3-10 billion cells/L, platelet count 160-380 billion/L, and normal lymphocyte count 1-4.8 billion lymphocytes/L; Males: red blood cell 4-6 trillion cells/L, hemoglobin 13-17 g/dL, hematocrit 38-49%, white blood cell count 3-10 billion cells/L, platelet count 135-320 billion/L, and normal lymphocyte count 1-4.8 billion lymphocytes/L; Age-matched control participants:
  • Renal function not within normal ranges (serum creatinine-estimated glomerular filtration rate >> 60 mL/min)
  • Hepatic function not within normal ranges (alanine transaminase 0-35 IU/L, alkaline phosphatase 30-120 IU/L, total bilirubin 2-17 micromoles/L)
  • Complete blood count NOT within ranges:; Females: red blood cell 4-5 trillion cells/L, hemoglobin 12-15 g/dL, hematocrit 34-45%, white blood cell count 3-10 billion cells/L, platelet count 160-380 billion/L, and normal lymphocyte count 1-4.8 billion lymphocytes/L; Males: red blood cell 4-6 trillion cells/L, hemoglobin 13-17 g/dL, hematocrit 38-49%, white blood cell count 3-10 billion cells/L, platelet count 135-320 billion/L, and normal lymphocyte count 1-4.8 billion lymphocytes/L
  • • Pain at rest and/or tissue loss due to PAD (Fontaine stage IV PAD)
  • No physical exam to assess exercise limitations in the past year
  • Currently pregnant or nursing
  • Diagnosis of multiple sclerosis or psoriasis
  • Ulcers, gangrene, or necrosis of the foot (Fontaine stage IV PAD)
  • Positive diagnosis of PAD
  • No physical exam to assess exercise limitations in the past year
  • Any exercise limitations as determined at last physical exam
  • Limited walking capacity from musculoskeletal injury
  • Currently pregnant or nursing

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 50 and 75 years old?

Where in United States

  • University of Nebraska OmahaOmaha, United StatesContact: Gwenael Layec, PhDTaking people

About the trial

What the trial wants to find out

Peripheral artery disease (PAD) is associated with elevated oxidative stress, and oxidative stress has been implicated as the cause of reduced endothelial reactivity in individuals with PAD. Endothelial function is important because the endothelium contributes to the dilation of arteries during exercise, thereby implicating impaired endothelial function as a mechanism contributing to exacerbated exercise-induced ischemia. Therefore, the purpose of this study is to test the hypothesis that acute exogenous diroximel fumarate (Vumerity) intake will improve antioxidant capacity, thereby reducing oxidative stress and improving vascular function and walking capacity in those with PAD. During this study, participants will be administered diroximel fumarate or a placebo, and the acute effects of diroximel fumarate on vascular function and walking capacity will be assessed. Vascular function and walking capacity will be assessed with flow-mediated dilation, arterial stiffness, head-up tilt test, blood biomarkers, near-infrared spectroscopy, and a treadmill test. There will be a follow-up visit to assess blood work after diroximel fumarate.

The 4 groups in the trial

  • Control: Vumerity intake, then PlaceboTreatment being tested

    Participants will receive a single dose of VUMERITY (diroximal fumarate, 462mg). After a minimum period of 7 days, they will then receive a single dose of the placebo (microcrystalline cellulose, 462 mg).

    Treatment: Vumerity and Placebo

  • Control: Placebo intake, then VumerityPlacebo, for comparison

    Participants will receive a single dose of placebo (microcrystalline cellulose, 462 mg). After a minimum period of 7 days, they will then receive a single dose of VUMERITY (diroximal fumarate, 462mg).

    Treatment: Vumerity and Placebo

  • PAD: Vumerity intake, then PlaceboTreatment being tested

    Participants with peripheral artery disease (PAD) will receive a single dose of VUMERITY (diroximal fumarate, 462mg). After a minimum period of 7 days, they will then receive a single dose of the placebo (microcrystalline cellulose, 462 mg).

    Treatment: Vumerity and Placebo

  • PAD: Placebo intake, then VumerityPlacebo, for comparison

    Participants with peripheral artery disease (PAD) will receive a single dose of placebo (microcrystalline cellulose, 462 mg). After a minimum period of 7 days, they will then receive a single dose of VUMERITY (diroximal fumarate, 462mg).

    Treatment: Vumerity and Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Impact of Nrf2 Activation on Macrovascular Function, Microvascular Function, Leg Function, and Walking Capacity in Patients With Peripheral Artery Disease
Plain-language title
Vumerity for blood vessel function and walking in peripheral artery diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06319339, who can take part
Record updated
24 June 2026